Astrazeneca

BMS: Buyer or buyout target?

admin — Wed, 07 May 2008 06:59:58 -0400

Market-watchers love to speculate. Their latest topic? Bristol-Myers Squibb, which has been paring away its "non-core" businesses over the last few months. Most recently, Bristol agreed to Read more...

AZ stock falls on Symbicort patent loss

admin — Wed, 07 May 2008 06:59:56 -0400

What a difference one patent ruling can make. AstraZeneca lost almost $1.3 billion in market value today after announcing that the European Patent Office yanked a patent covering its blockbuster Read more...

U.K. kids' antipsychotic use doubled

admin — Tue, 06 May 2008 06:59:55 -0400

The number of U.K. kids taking antipsychotics has doubled in recent years, expert say, as use of the meds has broadened to hyperactive and autistic children. The increase was most marked among 7- to Read more...

Drugmakers fighting for best U.K. deal

admin — Thu, 01 May 2008 06:59:55 -0400

As the U.K. nears a long-term drug-pricing deal with pharma firms, drugmakers are grousing about the fact that the government decided to renegotiate at all. You'll recall that late last year, the Read more...

AZ reaffirms whole-hog API outsourcing

admin — Wed, 30 Apr 2008 06:59:54 -0400

Remember last fall when AstraZeneca EVP David Smith said the company was looking to outsource most of its Read more...

SPOTLIGHT: AstraZeneca wants FDA ad review

admin — Mon, 28 Apr 2008 06:59:52 -0400

AstraZeneca is lobbying Congress for FDA review of television ads. Last fall lawmakers created a program that would require up-front scrutiny of DTC ads, but didn't give the FDA authority to collect Read more...

AZ, Amgen earnings flat; Shire sales leap

admin — Fri, 25 Apr 2008 06:59:54 -0400

It's a mixed bag of drugmaker earnings reports today, with two biggies posting flat results and two smaller firms chalking up respectable gains.AstraZeneca's profits suffered under restructuring Read more...

ALSO NOTED: Genzyme can't make Myozyme at Boston plant; Ranbaxy, Orchid forge drug-and-API deal;

admin — Tue, 22 Apr 2008 06:59:50 -0400

> FDA won't let Genzyme make its uber-expensive Pompe disease treatment Myozyme at its Boston plant because of a small difference between the batches of Myozyme Genzyme makes now and the new Read more...

Pharma fighting back in Washington

admin — Fri, 18 Apr 2008 06:59:56 -0400

Call it the backlash against the backlash. In the wake of the recent Read more...

Emerging markets drive global growth

admin — Wed, 16 Apr 2008 06:59:56 -0400

Without emerging healthcare markets like China and India, global pharma would be in a world of hurt. The global market for meds reached $712 billion last year, according to a new report from IMS Read more...